CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 179 enrolled
Drug / intervention
docetaxel +1 moredrug
Likely dose
docetaxel 30 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01004601
NCT01004601N/ACompleted
CompareCT.gov

Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taipei, Taiwan

Chang Gung Memorial Hospital·interventional·Posted Oct 30, 2009·Updated Oct 30, 2009

In Brief

A clinical study evaluating docetaxel and pemetrexed for Non Small Cell Lung Cancer. Completed, enrolled 179 participants across 1 site.

Detailed Summary

Docetaxel and pemetrexed have been validated for previously treated advanced non-small cell lung cancer (NSCLC); however, tolerability is a concern with the docetaxel (tri-weekly 75 mg/m2 schedule). The investigators conducted this study to compare the efficacy and toxicity of weekly low-dose docetaxel versus tri-weekly pemetrexed for previously treated advanced NSCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 30, 2009
Enrollment StartMar 1, 2005
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 16.7 years ago

Interventions

docetaxeldrug

patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.

pemetrexeddrug

patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.